Shandong Lukang Pharmaceutical Co., Ltd. Class ASSE: 600789

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

Sep 9, 2026 · Issued by Shandong Lukang Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Convening the 2026 Semi-annual Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Shandong Lukang Pharmaceutical Co., Ltd. Class A

"Shandong Lukang Pharmaceutical Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised FundsAug 29
"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on the Controlled Subsidiary Obtaining the Supplementary Application Approval Notice for Crisaborole Ointment and Becoming the Marketing Authorization Holder of the DrugAug 20
"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Notice of Approval for Marketing of Chemical API for Lenvatinib MesylateAug 13
"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration CertificateAug 8

All Shandong Lukang Pharmaceutical Co., Ltd. Class A news releases